[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563905":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":57,"collaborators":60,"id":64,"slug":32,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":32,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":32,"overallStatus":82,"whyStopped":32,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental group","EXPERIMENTAL","naltrexone 50mg",[13],"Drug: Naltrexone",{"label":15,"type":16,"description":17,"interventionNames":18},"comparison group","PLACEBO_COMPARATOR","placebo",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Naltrexone","naltrexone 50mg for 6 weeks",[9],[27],"Revia",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","placebo for 6 weeks",[15],null,[34],{"name":35,"affiliation":5,"role":36},"Yong Min Ahn, M.D, Ph.D","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"Dae Hun Kang, M.D","CONTACT","82 + 02-2072-2457","redlinnet@daum.net",[44],{"facility":5,"status":32,"city":45,"state":32,"zip":46,"country":47,"countryCode":32,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Seoul","03080","South Korea",{"type":49,"coordinates":50},"Point",[51,52],126.9784,37.566,{"lat":52,"lon":51},[55],{"name":39,"role":40,"phone":56,"phoneExt":32,"email":42},"82-2-2072-2457",{"type":36,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"Yong Min Ahn","Professor",[61],{"name":62,"class":63},"Whanin Pharmaceutical Company","INDUSTRY","100563905",false,"NCT06622239","Trial to Evaluate the Effects of Naltrexone in Nonsuicidal Self-injury","A Randomized, Double-Blinded Clinical Trial to Evaluate the Effects of Naltrexone in Improving Nonsuicidal Self-injurious Behavior","NiNsSIB","Inclusion Criteria:\n\n* Age: 16 years of age or older\n* Clinical interviews meet DSM-5\\'s nonsuicidal self-injury diagnostic criteria\n* Nonsuicidal self-injurious behavior has been observed more than once in the past two months\n* Obsessive Compulsive Drinking Scale general craving item 2 or more points (strong desire)\n* Self-injurious behavior continues even with 4 weeks of general psychiatric treatment for underlying disease\n* Anyone who can independently read and fill out the questionnaire and speak Korean\n* Who understand the written consent and voluntarily agree to participate in the study\n* Female participants of childbearing age must be negative on urine pregnancy test at screening\n\nExclusion Criteria:\n\n* currently in psychotic or manic conditions\n* currently experiencing serious suicidal thoughts\n* history of substance-related disorders including opioid\n* do not agree to use very effective contraception from the time of signing the test subject\\'s consent form to the end of study period (non-fertility women and postmenopausal women excluded from the contraception requirements)\n* Severe medical conditions (angina pectoris, myocardial infarction, arrhythmia, any cancer that is not in remission, hypothyroidism, hyperthyroidism, diabetes, hepatitis B, hepatitis C, epilepsy, dementia, HIV infection)\n* intellectual disability or organic brain damage\n* difficulty reading and writing Korean\n* taking opioid antagonists (methadone, buprenorphine, etc.)\n* on an opiate painkiller\n* currently opiate dependence\n* acute opiate withdrawal symptoms\n* naloxone-induced test is positive or the urine test is positive for opiates\n* have been sensitized to this drug\n* acute hepatitis, liver failure, severe liver failure\n* renal disease\n* hypersensitivity reaction to the main ingredient or other ingredients of this drug\n* a pregnant woman, a woman who may be pregnant, or a lactating woman\n* Since this drug contains lactose, genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc\n* active liver disease","ALL","16 Years",{"count":74,"type":75},150,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The goal of this clinical trial is to learn if naltrexone works to treat nonsuicidal self-injurious behavior in adolescents and adults.",[81],"Nonsuicidal Self-Injury","NOT_YET_RECRUITING","2026-05-20",{"date":85,"type":86},"2026-05-22","ACTUAL",{"date":88,"type":75},"2026-06-01",{"date":90,"type":75},"2027-05-31",{"name":5,"class":6},1]